tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KA

Kineta transitions from Nasdaq to OTC markets
The FlyKineta transitions from Nasdaq to OTC markets
8M ago
KA
Kintara announces Kineta reopens enrollment for VISTA-101 clinical trial
PremiumThe Fly
Kintara announces Kineta reopens enrollment for VISTA-101 clinical trial
9M ago
KA
KTRA
Kineta reopens enrollment for VISTA-101 clinical trial of KVA12123
PremiumThe Fly
Kineta reopens enrollment for VISTA-101 clinical trial of KVA12123
9M ago
KA
TuHURA enters exclusivity agreement with Kineta for KVA12123
PremiumThe Fly
TuHURA enters exclusivity agreement with Kineta for KVA12123
10M ago
KA
KTRA
Kineta enters exclusivity, right of first offer agreement with TuHURA Bioscience
PremiumThe Fly
Kineta enters exclusivity, right of first offer agreement with TuHURA Bioscience
10M ago
KA
Kineta Rolls Out New Stock and Cash Incentive Plans
PremiumCompany AnnouncementsKineta Rolls Out New Stock and Cash Incentive Plans
1y ago
8K
KA
Kineta Reports Progress in KVA12123 Cancer Trial
Premium
Company Announcements
Kineta Reports Progress in KVA12123 Cancer Trial
1y ago
8K
KA
Kineta presents data from Phase 1/2 VISTA-101 clinical trial at AACR
Premium
The Fly
Kineta presents data from Phase 1/2 VISTA-101 clinical trial at AACR
1y ago
KA
Kineta clears additional cohorts in Phase 1/2 VISTA-101 trial
PremiumThe Fly
Kineta clears additional cohorts in Phase 1/2 VISTA-101 trial
1y ago
KA
MRK
Kineta Explores Strategic Alternatives Amid Financial Struggles
PremiumCompany Announcements
Kineta Explores Strategic Alternatives Amid Financial Struggles
1y ago
8K
KA
Kineta to reduce workforce by 64% in corporate restructuring
PremiumThe Fly
Kineta to reduce workforce by 64% in corporate restructuring
1y ago
KA
Kineta Weighs Strategic Alternatives Amid Operational Challenges
PremiumCompany Announcements
Kineta Weighs Strategic Alternatives Amid Operational Challenges
1y ago
8K
KA
Kineta to present new preclinical data on KVA12123
PremiumThe FlyKineta to present new preclinical data on KVA12123
1y ago
KA
Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
Premium
The Fly
Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
1y ago
KA
Kineta publishes preclinical data on KVA12123
Premium
The Fly
Kineta publishes preclinical data on KVA12123
1y ago
KA
Kineta announces new data from VISTA-101 trial of KVA12123
PremiumThe Fly
Kineta announces new data from VISTA-101 trial of KVA12123
1y ago
KA
Kineta files to sell 890K shares of common stock for holders
PremiumThe Fly
Kineta files to sell 890K shares of common stock for holders
2y ago
KA
Kineta announces first patient dosed in Phase 1/2 VISTA-101 trial of KVA12123
PremiumThe Fly
Kineta announces first patient dosed in Phase 1/2 VISTA-101 trial of KVA12123
2y ago
KA
MRK
Kineta presents new preclinical data on anti-CD27 agonist
PremiumThe Fly
Kineta presents new preclinical data on anti-CD27 agonist
2y ago
KA
Kineta announces $3M registered direct offering priced at $3.37 per share
PremiumThe FlyKineta announces $3M registered direct offering priced at $3.37 per share
2y ago
KA
Kineta announces KVA12123 data from Phase 1/2 VISTA-101 trial
Premium
The Fly
Kineta announces KVA12123 data from Phase 1/2 VISTA-101 trial
2y ago
KA
Kineta enters research agreement with Fred Hutchinson Cancer Center
Premium
The Fly
Kineta enters research agreement with Fred Hutchinson Cancer Center
2y ago
KA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >